ID1 and non-small cell lung carcinoma: MiR‐381 inhibits ID‐1, thereby suppressing the activation of nuclear factor kappa‐light‐chain‐enhancer of activated B (NF‐κB) and inhibiting the expression of both B‐cell leukaemia/lymphoma‐2 (Bcl‐2) and Bcl‐XL, thus suppressing cell proliferation and inducing cell apoptosis in NSCLC, respectively.